Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-997-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.09 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its earnings results on Friday, August, 10th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.10. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to analysts' expectations of $4.14 million. Adamis Pharmaceuticals had a negative net margin of 258.54% and a negative return on equity of 100.32%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
3 brokers have issued 1-year price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $2.50 to $10.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 181.4% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (1/14/2019)
- 2. Maxim Group analysts commented, "The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced)." (9/12/2018)
- 3. HC Wainwright analysts commented, "EpiPen as an Exchange NASDAQ Value (M) $65.4 Market Cap (M) $101 Shares Outstanding (M) 45.1 3 Interest (M) 3.55 Cash (M) $37.9 Total Debt (M) $2.3 Cash balances and share count are projected based on 3Q18 capital raise." (8/23/2018)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
News articles about ADMP stock have been trending negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include Akorn (AKRX), Innate Pharma (IPHYF), Emisphere Technologies (EMIS), AMAG Pharmaceuticals (AMAG), Corbus Pharmaceuticals (CRBP), Rigel Pharmaceuticals (RIGL), Cytokinetics (CYTK), Urovant Sciences (UROV), Achillion Pharmaceuticals (ACHN), Stemline Therapeutics (STML), MannKind (MNKD), OvaScience (OVAS), Beyondspring (BYSI), Theratechnologies (THERF) and Concert Pharmaceuticals (CNCE).
What other stocks do shareholders of Adamis Pharmaceuticals own?
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman & Consultant (Age 75)
- Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
- Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
- Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
- Mr. Robert B. Rothermel, Consultant & Director (Age 75)
Who are Adamis Pharmaceuticals' major shareholders?
Adamis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.04%), Geode Capital Management LLC (0.64%), Geode Capital Management LLC (0.64%), Northern Trust Corp (0.35%), Raymond James & Associates (0.10%) and Barclays PLC (0.10%). View Institutional Ownership Trends for Adamis Pharmaceuticals.
Which institutional investors are selling Adamis Pharmaceuticals stock?
Which institutional investors are buying Adamis Pharmaceuticals stock?
ADMP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Barclays PLC, Geode Capital Management LLC, Geode Capital Management LLC, Raymond James & Associates, Oppenheimer & Co. Inc., Cambridge Investment Research Advisors Inc. and Jane Street Group LLC. View Insider Buying and Selling for Adamis Pharmaceuticals.
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $2.31.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $109.24 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
What is Adamis Pharmaceuticals' official website?
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
